[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-370727-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-370727-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","adherence-to-breast-screening-guidelines-and-breast-cancer-mortality-a-population-cohort-study","Adherence to breast screening guidelines and breast cancer mortality - a population cohort study","","Population-based breast screening programs detect cancer earlier, yet evidence on how adherence to screening guidelines affects breast-cancer mortality beyond stage at diagnosis remains limited. This population cohort study analyzed 48,927 women aged 51+ with first primary breast cancer in Ontario between 2010 and 2017, classifying participants as adherent, partial, or non-adherent screeners. Cause-specific hazard models estimated breast cancer death, adjusting for age, rurality, and prior cancer history while accounting for competing non-breast cancer mortality.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/adherence-to-breast-screening-guidelines-and-breast-cancer-mortality-a-population-cohort-study/370727/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/adherence-to-breast-screening-guidelines-and-breast-cancer-mortality-a-population-cohort-study/370727.png","ImageObject",300,407,{"name":42,"@type":43},"Cipher","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-30","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",13,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What was the study’s main goal?","Question",{"text":63,"@type":64},"To determine whether adherence to Ontario Breast Screening Program (OBSP) guidelines is associated with differences in the rate of death from breast cancer, in addition to cancer stage at diagnosis.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were participants grouped in the cohort?",{"text":68,"@type":64},"Women were classified as adherent screeners, partial screeners, or non-screeners based on whether their screening behavior met OBSP guideline adherence.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about breast cancer mortality?",{"text":72,"@type":64},"Non-screeners and non-adherent screeners had higher rates of breast cancer death compared with adherent screenings, while non-adherent screeners (screened at least once) still had a lower death rate than non-screeners.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},370727,1790363011,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":107,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},687208528416,"https://ap-avatar.wpscdn.com/davatar_9964176cb1d06d4a9deccf72a44ae3dc","Breast Cancer Research and Treatment (2025) 213:63–69  \n[https://doi.org/10.1007/s10549-025-07754-y](https://doi.org/10.1007/s10549-025-07754-y)  \nAdherence to breast screening guidelines and breast cancer mortality: a population cohort study  \nRebecca A. G. Christensen1,2 · Geoffrey M. Anderson1,3 · Shana J. Kim1 · Arian Aminoleslami3 · Jennifer D. Brooks1,4  \nReceived: 6 December 2024 / Accepted: 29 May 2025 / Published online: 3 July 2025 © The Author(s) 2025  \nAbstract  \nBackground Population-based breast screening programs diagnose cancers at earlier stage when they are easier to treat. Indeed, individuals screened as part of the Ontario Breast Screening Program (OBSP) are diagnosed with a lower stage of breast cancer than those who have never been screened. We sought to determine if adherence to OBSP guidelines is associated with differences in the rate of death from breast cancer in addition to cancer stage at diagnosis.  \nMethods 48,927 women ≥ 51 years diagnosed with a first primary breast cancer in Ontario 2010–2017 were included and classified as an adherent screener, partial screener, or non-screener. The cohort was developed using administrative health databases linked by Ontario Health. Cause-specific hazard ratios (HR) and 95% confidence intervals (CI) were used to examine the association between adherence to OBSP guidelines and the rate of breast cancer death adjusting for age, rurality, and history of a prior cancer diagnosis. Death from non-breast cancer causes was considered a competing risk.  \nResults Compared to adherent screenings, non-screeners and non-adherent screeners had higher rates of death from breast cancer (HR: 3.59, 95% CI 3.30–3.90 and HR: 1.69, 95% CI 1.47–1.95 respectively) . Further, non-adherent screeners (i.e., screened ≥ once) had a lower rate of breast cancer death than non-screeners (HR: 0.47, 95% CI 0 .41–0.54) .  \nInterpretation Individuals screened in the OBSP have a lower rate of death from breast cancer than non-screeners, even if they are not meeting screening guidelines. These findings suggest women should be encouraged to participate in breast screening regardless of their frequency of use.  \nKeywords Breast cancer · Screening · Mortality  \nIntroduction  \nBreast cancer is the most commonly diagnosed cancer in women worldwide [1, 2], and one in eight Canadian women will develop the disease in their lifetime [3] . Breast cancerrelated mortality has been on the decline since the 1980 s [4] This can be attributed to advancements in adjuvant  \n* Jennifer D. Brooks [jennifer.brooks@utoronto.ca](jennifer.brooks@utoronto.ca)  \n1 Public Health Sciences, Dalla Lana School of Public Health, University of Toronto, Toronto, ON, Canada  \n2 Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, ON, Canada  \n3 Institute of Health Policy, Management and Evaluation, University of Toronto, Toronto, ON, Canada  \n4 Dalla Lana School of Public Health Sciences, University of Toronto, 155 College St. HSB Rm 676, Toronto, ON M5T 3M7, Canada  \ntreatments (e.g., targeted therapies like tamoxifen, aromatase inhibitors and trastuzamab) [5], and the implementation of population-based screening programs [4, 6]. Screening with mammography diagnoses cancers at an earlier stage when they are easier to treat, leading to better outcomes.  \nProvincial breast cancer screening programs have existed in Canada since 1988 [7]. In Ontario, individuals ages 50 to 74 years who are not at high risk of breast cancer [8], are eligible to be screened with mammography every two years as part of the Ontario Breast Screening Program (OBSP), with annual screening available for women with extremely dense breasts or a strong family history [9](note: the OBSP expanded screening guidelines to include individuals in their forties in October 2024) . We previously showed that individuals who are screened according to OBSP guidelines are more likely to be diagnosed with a lower stage of breast cancer than those wh","cbCaid7zPvH3ifSh","https://ap.wps.com/l/cbCaid7zPvH3ifSh","pdf",629391,"English","# Abstract\n# Background\n# Methods\n## Study design, setting and population\n## Data sources\n# Results\n# Interpretation\n# Keywords\n# Introduction","[{\"question\":\"What was the study’s main goal?\",\"answer\":\"To determine whether adherence to Ontario Breast Screening Program (OBSP) guidelines is associated with differences in the rate of death from breast cancer, in addition to cancer stage at diagnosis.\"},{\"question\":\"How were participants grouped in the cohort?\",\"answer\":\"Women were classified as adherent screeners, partial screeners, or non-screeners based on whether their screening behavior met OBSP guideline adherence.\"},{\"question\":\"What did the results show about breast cancer mortality?\",\"answer\":\"Non-screeners and non-adherent screeners had higher rates of breast cancer death compared with adherent screenings, while non-adherent screeners (screened at least once) still had a lower death rate than non-screeners.\"}]","Adherence to breast screening guidelines and breast cancer mortality - a population cohort study | PDF",1790190081,18,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bb578a94bbc6ce7ae8064ff0b27df6a9.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b0f4f08c0705173ddd3e58c1a26b19be.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/882dcdf9d1bc6913728733d682efbdfb.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/3dc9ff28cea2745df91773f82d0d1f1e.webp",980,1301]